Benjamin Derman to Multiple Myeloma
This is a "connection" page, showing publications Benjamin Derman has written about Multiple Myeloma.
Connection Strength
10.956
-
Measurable Residual Disease and Decision-Making in Multiple Myeloma. Hematol Oncol Clin North Am. 2024 Apr; 38(2):477-495.
Score: 0.722
-
Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma. Blood Adv. 2023 10 10; 7(19):5703-5712.
Score: 0.710
-
MRD-guided treatment cessation in multiple myeloma. Lancet Haematol. 2023 11; 10(11):e867-e868.
Score: 0.709
-
Infection rates are high across the multiple myeloma continuum, not just with bispecific antibodies. Eur J Cancer. 2023 08; 189:112926.
Score: 0.694
-
A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma. Eur J Haematol. 2023 May; 110(5):564-570.
Score: 0.679
-
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study. JAMA Oncol. 2022 09 01; 8(9):1278-1286.
Score: 0.658
-
Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma. Blood Cancer J. 2022 07 11; 12(7):108.
Score: 0.651
-
Longitudinal Real-World Neuropathy and Patient-Reported Outcomes With Bortezomib and Lenalidomide in Newly Diagnosed Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2022 11; 22(11):e1000-e1008.
Score: 0.651
-
When a Monoclonal Gammopathy Is Not Multiple Myeloma. Am Soc Clin Oncol Educ Book. 2022 Apr; 42:1-10.
Score: 0.639
-
Knowing the unknowns in high risk multiple myeloma. Blood Rev. 2022 01; 51:100887.
Score: 0.613
-
Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation. Blood Cancer J. 2021 02 05; 11(2):19.
Score: 0.590
-
Sex differences in outcomes in multiple myeloma. Br J Haematol. 2021 02; 192(3):e66-e69.
Score: 0.581
-
Recommendations and outcomes from a geriatric assessment guided multidisciplinary clinic prior to autologous stem cell transplant in older patients. J Geriatr Oncol. 2021 05; 12(4):585-591.
Score: 0.580
-
Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis. Blood Cancer J. 2020 08 07; 10(8):80.
Score: 0.570
-
Clinician attitudes and practices toward measurable residual disease in multiple myeloma. Br J Haematol. 2020 08; 190(3):470-472.
Score: 0.563
-
Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study. J Immunother Cancer. 2020 01; 8(1).
Score: 0.547
-
Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial. Br J Haematol. 2023 12; 203(5):792-802.
Score: 0.177
-
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023 02; 24(2):139-150.
Score: 0.169
-
Genome-wide profiling of 5-hydroxymethylcytosines in circulating cell-free DNA reveals population-specific pathways in the development of multiple myeloma. J Hematol Oncol. 2022 08 16; 15(1):106.
Score: 0.164
-
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. Blood. 2020 11 26; 136(22):2513-2523.
Score: 0.146
-
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia. 2021 01; 35(1):18-30.
Score: 0.143